Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 30 September 1988:
Vol. 241. no. 4874, pp. 1813 - 1815
DOI: 10.1126/science.3175622
Prev | Table of Contents | Next

Articles

Science, Vol 241, Issue 4874, 1813-1815
Copyright © 1988 by American Association for the Advancement of Science

articles

Overexpression of metallothionein confers resistance to anticancer drugs

SL Kelley, A Basu, BA Teicher, MP Hacker, DH Hamer, and JS Lazo

Pharmaceutical Research and Development Division, Bristol Myers Co., Wallingford, CT 06492.

Resistance to antineoplastic agents is the major obstacle to curative therapy of cancer. Tumor cell lines with acquired resistance to the antineoplastic agent cis-diamminedichloroplatinum(II) overexpressed metallothionein and demonstrated cross-resistance to alkylating agents such as chlorambucil and melphalan. Human carcinoma cells that maintained high levels of metallothionein because of chronic exposure to heavy metals were resistant to cis-diamminedichloroplatinum(II), melphalan, and chlorambucil. Furthermore, cells transfected with bovine papilloma virus expression vectors containing DNA encoding human metallothionein-IIA were resistant to cis-diamminedichloroplatinum(II), melphalan, and chlorambucil but not to 5-fluorouracil or vincristine. Thus, overexpression of metallothionein represents one mechanism of resistance to a subset of clinically important anticancer drugs.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma.
M. A. Dimopoulos, V. L. Souliotis, A. Anagnostopoulos, C. Bamia, A. Pouli, I. Baltadakis, E. Terpos, S. A. Kyrtopoulos, and P. P. Sfikakis (2007)
Haematologica 92, 1505-1512
   Abstract »    Full Text »    PDF »
Functional Analysis of the Transcription Repressor PLU-1/JARID1B.
A. G. Scibetta, S. Santangelo, J. Coleman, D. Hall, T. Chaplin, J. Copier, S. Catchpole, J. Burchell, and J. Taylor-Papadimitriou (2007)
Mol. Cell. Biol. 27, 7220-7235
   Abstract »    Full Text »    PDF »
Metallothionein as a prognostic biomarker in breast cancer..
B.-H. Bay, R. Jin, J. Huang, and P.-H. Tan (2006)
Experimental Biology and Medicine 231, 1516-1521
   Abstract »    Full Text »    PDF »
Identification by Functional Cloning from a Retroviral cDNA Library of cDNAs for Ribosomal Protein L36 and the 10-kDa Heat Shock Protein that Confer Cisplatin Resistance.
D.-W. Shen, X.-J. Liang, T. Suzuki, and M. M. Gottesman (2006)
Mol. Pharmacol. 69, 1383-1388
   Abstract »    Full Text »    PDF »
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers..
M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al. (2006)
Mol. Cancer Ther. 5, 767-775
   Abstract »    Full Text »    PDF »
Expression of Metallothoinein Isoform 3 Is Restricted at the Post-Transcriptional Level in Human Bladder Epithelial Cells.
S. H. Garrett, S. Park, M. A. Sens, S. Somji, R. K. Singh, V. B. R. K. Namburi, and D. A. Sens (2005)
Toxicol. Sci. 87, 66-74
   Abstract »    Full Text »    PDF »
Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer.
W. P. Petros, P. J. Hopkins, S. Spruill, G. Broadwater, J. J. Vredenburgh, O. M. Colvin, W. P. Peters, R. B. Jones, J. Hall, and J. R. Marks (2005)
J. Clin. Oncol. 23, 6117-6125
   Abstract »    Full Text »    PDF »
Molecular Determinants of the Cytotoxicity of Platinum Compounds: The Contribution of in Silico Research.
A. Vekris, D. Meynard, M.-C. Haaz, M. Bayssas, J. Bonnet, and J. Robert (2004)
Cancer Res. 64, 356-362
   Abstract »    Full Text »    PDF »
Differential Expression of Metallothionein 1 and 2 Isoforms in Breast Cancer Lines with Different Invasive Potential: Identification of a Novel Nonsilent Metallothionein-1H Mutant Variant.
S.-K. Tai, O. J.-K. Tan, V. T.-K. Chow, R. Jin, J. L. Jones, P.-H. Tan, A. Jayasurya, and B.-H. Bay (2003)
Am. J. Pathol. 163, 2009-2019
   Abstract »    Full Text »    PDF »
Enhancement of Platinum-induced Cytotoxicity by O6-Benzylguanine.
M. L. Fishel, S. M. Delaney, L. D. Friesen, R. J. Hansen, E. G. Zuhowski, R. C. Moschel, M. J. Egorin, and M. E. Dolan (2003)
Mol. Cancer Ther. 2, 633-640
   Abstract »    Full Text »    PDF »
Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells.
A. Mansouri, L. D. Ridgway, A. L. Korapati, Q. Zhang, L. Tian, Y. Wang, Z. H. Siddik, G. B. Mills, and F. X. Claret (2003)
J. Biol. Chem. 278, 19245-19256
   Abstract »    Full Text »    PDF »
Prognostic Significance of Metallothionein in Human Gastrointestinal Cancer.
A. M. L. Janssen, W. van Duijn, F. J. G. M. Kubben, G. Griffioen, C. B. H. W. Lamers, J. H. J. M. van Krieken, C. J. H. van de Velde, and H. W. Verspaget (2002)
Clin. Cancer Res. 8, 1889-1896
   Abstract »    Full Text »    PDF »
Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells.
H. B. Deng, H. K. Parekh, K.-C. Chow, and H. Simpkins (2002)
J. Biol. Chem. 277, 15035-15043
   Abstract »    Full Text »    PDF »
Overexpression of Metallothionein-II Sensitizes Rodent Cells to Apoptosis Induced by DNA Cross-linking Agent through Inhibition of NF-kappa B Activation.
E. Papouli, M. Defais, and F. Larminat (2002)
J. Biol. Chem. 277, 4764-4769
   Abstract »    Full Text »    PDF »
Two Nuclear Proteins, Cin5 and Ydr259c, Confer Resistance to Cisplatin in Saccharomyces cerevisiae.
T. Furuchi, H. Ishikawa, N. Miura, M. Ishizuka, K. Kajiya, S. Kuge, and A. Naganuma (2001)
Mol. Pharmacol. 59, 470-474
   Abstract »    Full Text »
Chlorambucil Drug Resistance in Chronic Lymphocytic Leukemia: The Emerging Role of DNA Repair.
L. Panasci, J.-P. Paiement, G. Christodoulopoulos, A. Belenkov, A. Malapetsa, and R. Aloyz (2001)
Clin. Cancer Res. 7, 454-461
   Abstract »    Full Text »
Transcriptional Activation of the Human HMG1 Gene in Cisplatin-resistant Human Cancer Cells.
G. Nagatani, M. Nomoto, H. Takano, T. Ise, K. Kato, T. Imamura, H. Izumi, K. Makishima, and K. Kohno (2001)
Cancer Res. 61, 1592-1597
   Abstract »    Full Text »
Metallothionein Expression Protects against Carbon Tetrachloride-Induced Hepatotoxicity, but Overexpression and Dietary Zinc Supplementation Provide No Further Protection in Metallothionein Transgenic and Knockout Mice.
S. R. Davis, D. A. Samuelson, and R. J. Cousins (2001)
J. Nutr. 131, 215-222
   Abstract »    Full Text »
Intrinsic Resistance to Chemotherapeutic Agents in Murine Osteosarcoma Cells.
H. Takeshita, K. Kusuzaki, T. Ashihara, M. C. Gebhardt, H. J. Mankin, and Y. Hirasawa (2000)
J. Bone Joint Surg. Am. 82, 963
   Abstract »    Full Text »
Transactivation of the Metallothionein Promoter in Cisplatin-Resistant Cancer Cells: a Specific Gene Therapy Strategy.
D. Vandier, V. Calvez, L. Massade, A. Gouyette, L. Mickley, T. Fojo, and O. Rixe (2000)
J Natl Cancer Inst 92, 642-647
   Abstract »    Full Text »    PDF »
p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series.
A. Cabelguenne, H. Blons, I. de Waziers, F. Carnot, A.-M. Houllier, T. Soussi, D. Brasnu, P. Beaune, O. Laccourreye, and P. Laurent-Puig (2000)
J. Clin. Oncol. 18, 1465-1473
   Abstract »    Full Text »    PDF »
Expression of Metallothionein II in Intestinal Metaplasia, Dysplasia, and Gastric Cancer.
M. P. A. Ebert, T. Günther, J. Hoffmann, J. Yu, S. Miehlke, H. U. Schulz, A. Roessner, M. Korc, and P. Malfertheiner (2000)
Cancer Res. 60, 1995-2001
   Abstract »    Full Text »
A Clinical Study of Hypoxia and Metallothionein Protein Expression in Squamous Cell Carcinomas.
J. A. Raleigh, S.-C. Chou, D. P. Calkins-Adams, C. A. Ballenger, D. B. Novotny, and M. A. Varia (2000)
Clin. Cancer Res. 6, 855-862
   Abstract »    Full Text »
Molecular Dynamics Simulation of Metallothionein-Drug Complexes.
Z. Szilágyi and C. Fenselau (2000)
Drug Metab. Dispos. 28, 174-179
   Abstract »    Full Text »
Suppression of Metallothionein Gene Expression in a Rat Hepatoma Because of Promoter-specific DNA Methylation.
K. Ghoshal, S. Majumder, Z. Li, X. Dong, and S. T. Jacob (2000)
J. Biol. Chem. 275, 539-547
   Abstract »    Full Text »    PDF »
Biological Monitoring of Exposure to Cisplatin in Rats Using SOS Chromotest.
S.-J. Lee, J.-H. Hur, and B.-H. Lee (2000)
International Journal of Toxicology 19, 13-17
   Abstract »    PDF »
Metallothionein Is Overexpressed by Hamster Fibroblasts Selected for Growth in 15 pM Folinic Acid and Provides a Growth Advantage in Low Folate.
W.-Y. Zhu and P. W. Melera (1999)
Cancer Res. 59, 4194-4199
   Abstract »    Full Text »    PDF »
Covalent Sequestration of Phosphoramide Mustard by Metallothionein---An In Vitro Study.
D. Wei, D. Fabris, and C. Fenselau (1999)
Drug Metab. Dispos. 27, 786-791
   Abstract »    Full Text »
Inhibition of Buthionine Sulfoximine-Enhanced Doxorubicin Toxicity in Metallothionein Overexpressing Transgenic Mouse Heart.
H.-Y. Wu and Y. J. Kang (1998)
J. Pharmacol. Exp. Ther. 287, 515-520
   Abstract »    Full Text »
Covalent Sequestration of the Nitrogen Mustard Mechlorethamine by Metallothionein.
M. Antoine, D. Fabris, and C. Fenselau (1998)
Drug Metab. Dispos. 26, 921-926
   Abstract »    Full Text »
Identification of semaphorin E as a non-MDR drug resistance gene of human cancers.
T. Yamada, R. Endo, M. Gotoh, and S. Hirohashi (1997)
PNAS 94, 14713-14718
   Abstract »    Full Text »    PDF »
The Protective Effect of Metallothionein Against Lipid Peroxidation Caused by Retinoic Acid in Human Breast Cancer Cells.
D. Hurnanen, H. M. Chan, and S. Kubow (1997)
J. Pharmacol. Exp. Ther. 283, 1520-1528
   Abstract »    Full Text »
Enhanced Apoptosis in Metallothionein Null Cells.
Y. Kondo, J. M. Rusnak, D. G. Hoyt, C. E. Settineri, B. R. Pitt, and J. S. Lazo (1997)
Mol. Pharmacol. 52, 195-201
   Abstract »    Full Text »
Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-Glycoprotein-Positive, Murine Osteosarcoma Cell Lines.
H. TAKESHITA, M. C. GEBHARDT, D. S. SPRINGFIELD, K. KUSUZAKI, and H. J. MANKIN (1996)
J. Bone Joint Surg. Am. 78, 366-75
   Abstract »    Full Text »
Binding of the Escherichia coli UvrAB Proteins to the DNA Mono- and Diadducts of cis-[N-2-Amino-N-2-methylamino-2,2,1-bicycloheptane]dichloroplatinum(II) and Cisplatin.
B. Lambert, J.-L. Jestin, P. Bréhin, C. Oleykowski, A. T. Yeung, P. Mailliet, C. Prétot, J.-B. L. Pecq, A. Jacquemin-Sablon, and J.-C. Chottard (1995)
J. Biol. Chem. 270, 21251-21257
   Abstract »    Full Text »    PDF »
Enhanced Sensitivity to Oxidative Stress in Cultured Embryonic Cells from Transgenic Mice Deficient in Metallothionein I and II Genes.
J. S. Lazo, Y. Kondo, D. Dellapiazza, A. E. Michalska, K. H. A. Choo, and B. R. Pitt (1995)
J. Biol. Chem. 270, 5506-5510
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)